Compare Alphabet Inc Class A (GOOGL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Summit Therapeutics Inc — how do they compare? Alphabet Inc Class A trades at $371.62 (market cap $4.52T), while Summit Therapeutics Inc trades at $13.9 (market cap $11.70B). The key difference: Alphabet Inc Class A is far larger — about 386.3× Summit Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GOOGL | SMMT | |
|---|---|---|
Market Cap | $4.52T | $11.70B |
Sector | Media | Health |
52-Week High | $402.62 | $29.32 |
52-Week Low | $182.97 | $13.05 |
Enterprise Value | $4.49T | $11.12B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) stock trades at $370.92, up 3.17% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $350B in 2024 to $402.8B in 2025 and net income surging 32% to $132.2B. Recent quarterly earnings consistently beat expectations, and the company initiated a dividend in 2026. Analyst sentiment remains overwhelmingly positive with 85% buy ratings and a $431.78 consensus price target, suggesting 16% upside potential.
The outlook for GOOGL appears favorable given strong AI-driven growth in cloud and advertising, expanding profitability margins, and solid cash flow generation. Key risks include regulatory scrutiny of antitrust practices, competitive pressures in AI and cloud services, and potential market volatility affecting tech valuations. The stock's current valuation at 28.29x P/E reflects premium pricing for its growth trajectory.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
